• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

A novel validated, imaging-based risk model may predict poststroke epilepsy more accurately than existing tools

byPaary Balakumar, MD, MScandSimon Pan, MD
January 12, 2026
in Chronic Disease, Neurology
Reading Time: 3 mins read
Ischemic stroke collage: an engraved brain with one artery traced in blue beside a glass hourglass on graph paper
Share on FacebookShare on TwitterShare on LinkedIn

1. The IsCHEMiA score is a validated, imaging-based risk model that more accurately predicts poststroke epilepsy than existing tools across multiple international cohorts.

2. Incorporation of infarct size and hemorrhagic transformation identifies high-risk patients who may benefit from closer monitoring and future antiepileptogenic interventions.

Evidence Rating Level: 2 (Good)

Study Rundown: Poststroke epilepsy is a common and morbid complication of ischemic stroke, yet existing risk scores incompletely capture neuroimaging predictors of epileptogenesis. This study developed and internationally validated the IsCHEMiA score, a six-item clinical and imaging-based tool to predict poststroke epilepsy after first-ever ischemic stroke. Using a prospective U.S. stroke registry and competing risk regression with mortality as a competing event, the authors identified infarct size ≥5 cm, cortical involvement, hemorrhagic transformation, early symptomatic seizures, middle cerebral artery involvement, and age younger than 65 years as independent predictors. The score was externally validated in three cohorts from Hong Kong and Japan, demonstrating strong discrimination (c-statistics 0.826–0.870) and good calibration. IsCHEMiA consistently outperformed existing SeLECT-based scores. Low scores predicted minimal seizure risk, whereas scores ≥8 identified patients with very high long-term epilepsy risk. The IsCHEMiA score provides a practical framework for individualized poststroke seizure risk stratification and future preventive trials.

Click to read the study in Neurology

Relevant Reading: Influence of seizures on stroke outcomes: a large multicenter study

RELATED REPORTS

One in four National Football League (NFL) players who died between 2016-2021 had evidence of chronic traumatic encephalopathy

Brain-predicted age difference may reliably predict dementia progression

FDA approvedFor ischemic stroke: Sunharbo (asundexian), Nov 9, 2026→

In-Depth [Prospective Cohort Study]: 

Poststroke epilepsy (PSE) is a frequent and clinically significant complication of ischemic stroke, affecting approximately 4–6% of patients within the first year and up to 8% within five years. PSE is associated with worse functional recovery, reduced quality of life, and increased mortality. Despite this burden, there is currently insufficient evidence to support routine primary antiseizure medication prophylaxis after stroke. Existing prediction tools, such as the SeLECT and SeLECT2.0 scores, have provided risk stratification but do not incorporate several key neuroimaging features known to be associated with epileptogenesis. The authors therefore sought to develop and internationally validate a novel, imaging-based risk score to predict PSE following the first-ever acute ischemic stroke.

This study used a prospective stroke registry from Massachusetts General Hospital (MGH) to derive the prediction model, including adults admitted with first-ever ischemic stroke between 2016 and 2018. Patients with prior stroke, prior epilepsy, primary intracranial hemorrhage, concurrent antiseizure medication use, or insufficient follow-up were excluded. Neuroimaging was systematically reviewed to characterize infarct size, cortical involvement, vascular territory, and hemorrhagic transformation. Competing risk regression was performed with all-cause mortality as a competing event, and backward stepwise elimination using the Akaike Information Criterion was used to derive the final multivariable model. External validation was conducted in three independent cohorts from Hong Kong (Queen Mary Hospital and Ruttonjee Hospital) and Japan (National Cerebral and Cardiovascular Center).

The derivation cohort included 1,436 patients, and the validation cohorts contributed an additional 2,534 patients. Across the overall study population, PSE occurred in 5.5% of patients. Univariable analyses identified several predictors previously described in the literature, as well as novel neuroimaging factors. After multivariable adjustment, six independent predictors remained and were incorporated into the final IsCHEMiA score: infarct size ≥5 cm, cortical involvement, hemorrhagic transformation, early symptomatic seizures within seven days of stroke, middle cerebral artery territory involvement, and age younger than 65 years. Each variable was assigned a weighted point value based on its adjusted subdistribution hazard ratio.

The IsCHEMiA score demonstrated excellent discrimination in the derivation cohort, with a c-statistic of 0.870, and consistent performance in all validation cohorts (c-statistics ranging from 0.826 to 0.857). Calibration at one and three years after stroke was good, with close agreement between predicted and observed PSE risk. Importantly, the IsCHEMiA score outperformed both SeLECT and SeLECT2.0 in most cohorts. Risk stratification showed clinically meaningful gradients: an IsCHEMiA score of 3 predicted a low risk of PSE (approximately 2% at one year and 6% at five years), whereas scores of 8 or higher were associated with a very high risk (approximately 67% at one year and 78% at five years).

The authors conclude that IsCHEMiA is a practical, imaging-informed, and internationally validated tool for predicting PSE in modern stroke care. By identifying patients at high risk, the score may guide closer monitoring, targeted EEG use, and future trials of antiepileptogenic therapies, while reinforcing current recommendations against routine prophylactic antiseizure medication use in low-risk patients.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: acute ischemic strokeanti-epileptic drugs (AED)epilepsyHemorrhagic Strokeneurology
Previous Post

Large language models (LLMs) substantially improved patient comprehension of discharge summaries

Next Post

Patient and provider characteristics associated with difficult clinical encounters

RelatedReports

Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Chronic Disease

One in four National Football League (NFL) players who died between 2016-2021 had evidence of chronic traumatic encephalopathy

August 27, 2026
Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Chronic Disease

Brain-predicted age difference may reliably predict dementia progression

August 19, 2026
No difference in mortality for intensive versus standard reduction in blood pressure in intracerebral hemorrhage: The ATACH-2 trial
Emergency

Diffusion-weighted imaging may aid in prognostication for intracerebral hemorrhage

August 18, 2026
Fatty liver disease collage: an engraved liver dotted with pale fat droplets beside a tray of three capped blood tubes
Weekly Rewinds

2 Minute Medicine Rewind August 17, 2026

August 17, 2026
Next Post
Clinic visits collage: a bearded man listening at a wooden desk with a closed folder and a glass of water

Patient and provider characteristics associated with difficult clinical encounters

Prostate cancer outlook collage: a whole walnut in its shell, a round magnifying glass and a small brass compass

New model enhances prediction of prostate cancer-specific mortality

Surgical care collage: an operating light over a draped table, a tray with a surgical cap and mask, and a closed case

Surgery-induced weight loss may be associated with lower mortality rates in women with obesity but not men

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.